Results 201 to 210 of about 173,798 (309)

Psilocybin as a novel treatment for chronic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey   +3 more
wiley   +1 more source

Neuromelanin, iron and MRI measurements in midbrain tissues of Parkinson's and Alzheimer's subjects. [PDF]

open access: yesFront Aging Neurosci
Zucca FA   +11 more
europepmc   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

open access: yesBritish Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller   +3 more
wiley   +1 more source

Human microglia in brain assembloids display region-specific diversity and respond to hyperexcitable neurons carrying <i>SCN2A</i> mutation. [PDF]

open access: yesSci Adv
Wu J   +19 more
europepmc   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman   +3 more
wiley   +1 more source

Mitochondrial DNA Damage in Substantia Nigra Pars Compacta Astrocytes Exacerbates Dopaminergic Neuron Loss in a 6-Hydroxydopamine Mouse Model of Parkinsonism. [PDF]

open access: yesCell Mol Neurobiol
Ayala DA   +9 more
europepmc   +1 more source

Schedule‐dependent neuroprotection by pioglitazone in a novel model of α‐synucleinopathy in rats: Integrated behavioural and histological outcomes

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose α‐Synucleinopathies are neurodegenerative disorders characterized by the aggregation and propagation of misfolded α‐synuclein. In Parkinson's disease (PD), the most common α‐synucleinopathy, the progression of motor and nonmotor deficits, and dopaminergic neuron loss, are closely linked to the spreading of misfolded α‐synuclein ...
Alberto Santiago‐Balmaseda   +5 more
wiley   +1 more source

SNCA triplication disrupts proteostasis and extracellular architecture prior to neurodegeneration in human midbrain organoids. [PDF]

open access: yesNPJ Parkinsons Dis
Statoulla E   +11 more
europepmc   +1 more source

Cortical‐Hypothalamic Assembloids Uncover the Cortical Regulation of Hypothalamic Responses to Fatty Acid

open access: yesCell Proliferation, EarlyView.
By assembling cortical‐hypothalamic circuits, we show that cortical input protects hypothalamic neurons from fatty acid‐induced damage, which activates PGC1α to boost mitochondrial function. This reveals a cortico‐hypothalamic axis that defends against metabolic stress.
Mengdan Tao   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy